Zhejiang Hisun Pharmaceutical Co., Ltd. (SHA:600267)
China · Delayed Price · Currency is CNY 11.52
-0.13 (-1.12%)
Apr 28, 2026, 3:00 PM CST
SHA:600267 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 10,180 | 10,421 | 10,125 | 10,158 | 11,709 | 11,902 |
Other Revenue | 128.76 | 128.76 | 215.22 | 215.53 | 328.14 | 234.07 |
| 10,308 | 10,550 | 10,340 | 10,373 | 12,037 | 12,136 | |
Revenue Growth (YoY) | 6.36% | 2.02% | -0.32% | -13.82% | -0.82% | 6.89% |
Cost of Revenue | 5,938 | 5,938 | 6,187 | 6,338 | 7,119 | 7,331 |
Gross Profit | 4,370 | 4,612 | 4,154 | 4,035 | 4,918 | 4,806 |
Selling, General & Admin | 2,922 | 2,922 | 3,000 | 3,258 | 3,431 | 3,453 |
Research & Development | 478.54 | 478.54 | 357.69 | 391.95 | 428.69 | 372.8 |
Other Operating Expenses | -398.17 | 76.24 | 52.03 | 45.6 | 111.62 | 111.52 |
Operating Expenses | 3,052 | 3,527 | 3,496 | 3,719 | 3,962 | 3,950 |
Operating Income | 1,318 | 1,085 | 657.14 | 316.55 | 956.29 | 855.41 |
Interest Expense | -100.08 | -100.08 | -155.9 | -215.4 | -283.12 | -345.81 |
Interest & Investment Income | 20.85 | 20.85 | 181.46 | 89.22 | 51.57 | 121.41 |
Currency Exchange Gain (Loss) | -4.54 | -4.54 | 2.67 | 3.42 | -0.58 | -4.79 |
Other Non Operating Income (Expenses) | -1.15 | -1.16 | 0.29 | -2.86 | -5.55 | -2.34 |
EBT Excluding Unusual Items | 1,233 | 999.77 | 685.66 | 190.94 | 718.61 | 623.88 |
Gain (Loss) on Sale of Investments | -117.88 | -117.88 | -14.93 | 0.28 | -135.77 | -17.77 |
Gain (Loss) on Sale of Assets | 2.56 | 2.56 | -0.56 | -55.24 | -2.06 | -46.71 |
Asset Writedown | -73.03 | -73.03 | -2.83 | -149.46 | -0.57 | -2.24 |
Other Unusual Items | 3.96 | 3.96 | 50.74 | -69.38 | 103.22 | 87.03 |
Pretax Income | 1,048 | 815.38 | 718.07 | -82.87 | 683.42 | 644.19 |
Income Tax Expense | 339.5 | 267.89 | 126.76 | 14.15 | 192.19 | 133.56 |
Earnings From Continuing Operations | 708.95 | 547.49 | 591.31 | -97.01 | 491.23 | 510.63 |
Minority Interest in Earnings | -6.78 | -6.78 | 9.87 | 3.84 | -2.37 | -23.74 |
Net Income | 702.17 | 540.71 | 601.18 | -93.17 | 488.86 | 486.89 |
Net Income to Common | 702.17 | 540.71 | 601.18 | -93.17 | 488.86 | 486.89 |
Net Income Growth | 28.40% | -10.06% | - | - | 0.40% | 16.71% |
Shares Outstanding (Basic) | 1,177 | 1,175 | 1,156 | 1,165 | 1,164 | 1,132 |
Shares Outstanding (Diluted) | 1,177 | 1,175 | 1,156 | 1,165 | 1,164 | 1,132 |
Shares Change (YoY) | 1.79% | 1.67% | -0.73% | 0.06% | 2.80% | 16.71% |
EPS (Basic) | 0.60 | 0.46 | 0.52 | -0.08 | 0.42 | 0.43 |
EPS (Diluted) | 0.60 | 0.46 | 0.52 | -0.08 | 0.42 | 0.43 |
EPS Growth | 26.14% | -11.54% | - | - | -2.33% | - |
Free Cash Flow | - | 1,655 | 1,946 | 1,263 | 1,535 | 1,114 |
Free Cash Flow Per Share | - | 1.41 | 1.68 | 1.08 | 1.32 | 0.98 |
Dividend Per Share | 0.210 | 0.210 | 0.210 | - | 0.170 | 0.140 |
Dividend Growth | - | - | - | - | 21.43% | 182.26% |
Gross Margin | 42.39% | 43.71% | 40.17% | 38.90% | 40.86% | 39.60% |
Operating Margin | 12.78% | 10.28% | 6.35% | 3.05% | 7.95% | 7.05% |
Profit Margin | 6.81% | 5.13% | 5.81% | -0.90% | 4.06% | 4.01% |
Free Cash Flow Margin | - | 15.69% | 18.82% | 12.17% | 12.75% | 9.18% |
EBITDA | 2,242 | 2,039 | 1,730 | 1,353 | 1,985 | 1,797 |
EBITDA Margin | 21.75% | 19.32% | 16.73% | 13.04% | 16.49% | 14.81% |
D&A For EBITDA | 924.07 | 953.91 | 1,073 | 1,036 | 1,029 | 941.92 |
EBIT | 1,318 | 1,085 | 657.14 | 316.55 | 956.29 | 855.41 |
EBIT Margin | 12.78% | 10.28% | 6.35% | 3.05% | 7.95% | 7.05% |
Effective Tax Rate | 32.38% | 32.86% | 17.65% | - | 28.12% | 20.73% |
Revenue as Reported | 10,550 | 10,550 | 10,340 | 10,373 | 12,037 | 12,136 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.